Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Recent News
Upcoming Events
Tuesday, October 11, 2016
Jefferies Gene Editing/Therapy Summit
Monday, November 7, 2016
Credit Suisse Healthcare Conference
Stock Information
NASDAQ  |  NTLA (Common Stock)
$17.00 - 0.02
Stock chart for: NTLA.O.  Currently trading at $17.00 with a 52 week high of $30.40 and a 52 week low of $16.60.
09/29/16 4:15 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
IR Contacts

John Graziano
Trout Group, LLC

Chad Rubin
Trout Group, LLC